📊 XBIO Key Takeaways
Is Xenetic Biosciences, Inc. (XBIO) a Good Investment?
Xenetic Biosciences exhibits explosive revenue growth (1911% YoY) but remains deeply unprofitable with negative operating margins (-62.2%) and ongoing cash burn (-$536.4K quarterly). While the balance sheet is fortress-like with $7.3M cash and minimal debt, the company's failure to convert substantial revenue into either gross profit or positive operating cash flow raises fundamental questions about business model viability and the quality of growth.
Why Buy Xenetic Biosciences, Inc. Stock? XBIO Key Strengths
- Exceptional revenue growth of 1911% YoY demonstrates successful commercialization or market traction
- Strong liquidity position with $7.3M cash and current ratio of 7.93x provides 3-4 year operational runway
- Minimal leverage (Debt/Equity 0.03x) provides financial flexibility and low refinancing risk
XBIO Stock Risks: Xenetic Biosciences, Inc. Investment Risks
- Severe unprofitability with -62.2% operating margin and -56.6% net margin despite significant revenue
- Negative operating cash flow of -$536.4K indicates growth is not generating real cash, only accounting revenue
- Zero gross profit reporting is anomalous—revenue entirely consumed by COGS or indicates potential revenue quality issues
- Micro-cap scale ($7.9M assets) limits resources to sustain operations and achieve scale economics
Key Metrics to Watch
- Path to positive gross margin and operating profitability
- Quarterly operating cash flow trend—must return to positive within 2-3 quarters
- Revenue sustainability—confirm 1911% growth is repeatable or normalize
Xenetic Biosciences, Inc. (XBIO) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 7.93x current ratio provides a solid financial cushion.
XBIO Profit Margin, ROE & Profitability Analysis
XBIO vs Healthcare Sector: How Xenetic Biosciences, Inc. Compares
How Xenetic Biosciences, Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Xenetic Biosciences, Inc. Stock Overvalued? XBIO Valuation Analysis 2026
Based on fundamental analysis, Xenetic Biosciences, Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Xenetic Biosciences, Inc. Balance Sheet: XBIO Debt, Cash & Liquidity
XBIO Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Xenetic Biosciences, Inc.'s revenue has grown significantly by 156% over the 5-year period, indicating strong business expansion. The most recent EPS of $-2.57 indicates the company is currently unprofitable.
XBIO Revenue Growth, EPS Growth & YoY Performance
XBIO Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $593.3K | -$456.4K | $-0.20 |
| Q3 2025 | $614.2K | -$436.7K | $-0.28 |
| Q2 2025 | $589.9K | -$688.7K | $-0.45 |
| Q1 2025 | $510.8K | -$903.1K | $-0.59 |
| Q3 2024 | $611.2K | -$436.7K | $-0.28 |
| Q2 2024 | $651.0K | -$1.1M | $-0.69 |
| Q1 2024 | $510.8K | -$856.6K | $-0.56 |
| Q3 2023 | $414.3K | -$804.0K | $-0.56 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Xenetic Biosciences, Inc. Dividends, Buybacks & Capital Allocation
XBIO SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Xenetic Biosciences, Inc. (CIK: 0001534525)
📋 Recent SEC Filings
❓ Frequently Asked Questions about XBIO
What is the AI rating for XBIO?
Xenetic Biosciences, Inc. (XBIO) has an AI rating of SELL with 72% confidence, based on fundamental analysis of SEC EDGAR filings.
What are XBIO's key strengths?
Claude: Exceptional revenue growth of 1911% YoY demonstrates successful commercialization or market traction. Strong liquidity position with $7.3M cash and current ratio of 7.93x provides 3-4 year operational runway.
What are the risks of investing in XBIO?
Claude: Severe unprofitability with -62.2% operating margin and -56.6% net margin despite significant revenue. Negative operating cash flow of -$536.4K indicates growth is not generating real cash, only accounting revenue.
What is XBIO's revenue and growth?
Xenetic Biosciences, Inc. reported revenue of $806.9K.
Does XBIO pay dividends?
Xenetic Biosciences, Inc. does not currently pay dividends.
Where can I find XBIO SEC filings?
Official SEC filings for Xenetic Biosciences, Inc. (CIK: 0001534525) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is XBIO's EPS?
Xenetic Biosciences, Inc. has a diluted EPS of $-0.20.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is XBIO a good stock to buy right now?
Based on our AI fundamental analysis in May 2026, Xenetic Biosciences, Inc. has a SELL rating with 72% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is XBIO stock overvalued or undervalued?
Valuation metrics for XBIO: ROE of -6.6% (sector avg: 15%), net margin of -56.6% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy XBIO stock in 2026?
Our dual AI analysis gives Xenetic Biosciences, Inc. a combined SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is XBIO's free cash flow?
Xenetic Biosciences, Inc.'s operating cash flow is $-536.4K, with capital expenditures of $0.0. FCF margin is -66.5%.
How does XBIO compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin -56.6% (avg: 12%), ROE -6.6% (avg: 15%), current ratio 7.93 (avg: 2).